Respiratory syncytial virus prophylaxis with nirsevimab: impact beyond hospitalisations

After decades of unsuccessful efforts to prevent respiratory syncytial virus (RSV) infection, the development of new vaccines and monoclonal antibodies has brought renewed optimism. As these tools are implemented across health systems with differing policies, careful evaluations are essential to ensure effective and equitable prevention. In this context, the study by Perramon-Malavez et al.,1 investigates how a population-based immunisation programme using nirsevimab for infants impacts emergency department (ED) visits and hospitalisations for bronchiolitis in Catalonia (Spain).